{
    "Trade/Device Name(s)": [
        "DIAVUE Prudential Blood Glucose Monitoring System",
        "DIAVUE Control Solution",
        "DIAVUE Blood Glucose Test Strips"
    ],
    "Submitter Information": "BioCare Corporation",
    "510(k) Number": "K122307",
    "Predicate Device Reference 510(k) Number(s)": [
        "K082482",
        "K093724"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGA",
        "NBW",
        "JJX"
    ],
    "Summary Letter Date": "April 5, 2013",
    "Summary Letter Received Date": "March 28, 2013",
    "Submission Date": "February 25, 2013",
    "Regulation Number(s)": [
        "21CFR862.1345",
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Glucose test system",
        "Quality Control Material (Assayed and Unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DIAVUE Prudential Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical biosensor technology",
        "Glucose oxidase"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Control",
        "Test Strip"
    ],
    "Document Summary": "FDA 510(k) summary for DIAVUE Prudential Blood Glucose Monitoring System and DIAVUE Control Solution for self-monitoring blood glucose in capillary whole blood",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood by people with diabetes at home for monitoring diabetes control; control solutions verify user technique and system function; not for diagnosis, screening, or neonatal use",
    "fda_folder": "Clinical Chemistry"
}